Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 115

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 115
---
 and our own internal directives. We have outsourced some of our production under supply contracts associated with acquisitions of products or businesses or with Sanofi plant divestitures, or to establish a local presence to capitalize on growth in emerging markets. Our pharmaceutical subcontractors follow our general quality and logistics policies, as well as meeting other criteria. Our manufacturing activities require significant amounts of energy, the costs of which increased in 2022 and 2023 as a result of inflationary pressures and supply constraints due to the war in Ukraine. The Group uses supply contracts and hedging to mitigate those risks and costs. See “Item 3. Key Information — D. Risk Factors — Risks Relating to Our Business.” We also obtain active ingredients from third parties under collaboration agreements. This applies in particular to the monoclonal antibodies developed with Regeneron . Our production sites are divided into three categories: • global sites, which serve all markets: located mainly in Europe, these facilities are dedicated to the manufacture of our active ingredients , injectable products, and a number of our main solid-form products; • regional sites, which serve markets at regional level, giving us a strong industrial presence in emerging markets; and • local sites, which serve their domestic market only. Vaccines produces vaccines at various sites, with the main locations situated in France, the United States, Canada, India, Mexico and China. The pharmaceutical site at Le Trait (France) also contributes to Vaccines’ industrial operations by making its sterile filling facilities available for vaccine manufacturing. All of our production facilities are good manufacturing practice (GMP) compliant, in line with international regulations. Our main sites are approved by the FDA: • the Specialty Care facilities in the United States (Framingham MA and Northborough MA), France (Lyon Gerland, Vitry-sur- Seine, Le Trait), Germany (Frankfurt), Ireland (Waterford) and Belgium (Geel); • the General Medicines facilities in Germany (Frankfurt), France (Aramon, Sisteron, Ploermel, Ambarès and Tours), Italy (Anagni and Scoppito), Singapore (Jurong) and the United States (Ridgefield NJ); • the Vaccines facilities in France (Marcy l’Étoile, Le Trait, Val-de-Reuil and Neuville-sur-Saône), the United States (Swiftwater PA) and Canada (Toronto); and • the Opella facilities in France (Compiègne) and the United States (Ch